NEW YORK-- Drugmaker Shire said Friday it is recalling one batch of its Gaucher disease treatment Vpriv because particulate matter was discovered in some vials of the drug. Shire says revenue from Vpriv grew 12 percent to $342.7 million in 2013. The company had $4.93 billion in total revenue. U.S. shares of Shire PLC lost 23 cents to $154.61 in afternoon trading.» Read More
Good morning. Deborah Taft continues in the lead with a portfolio value of $2,582,726.3, up $366,000 Tuesday, from Monday's value of $2,216,726.30. Deborah's gamble on the ever-active CV Therapeutics paid off and secured her lead position. She went all in on Monday with a buy of 300,000 shares of CVTX at $6.75, and it looks like she caught a bottom...
Plaintiff Frank Schwaller sued Merck after his wife, Patricia, took Vioxx for 20 months for shoulder pain before dying from a heart attack in August 2003.
Most of our celebs had a slow day Monday, but James Cromwell "has been a machine" as someone said. Not only is he buying stocks, he's putting those bonus bucks to work--something the other celebs--and you non-celebs should be using to your advantage. Willie Garson used them to put Johnny Bench back in last place.
Hey folks. Here's the best performing trades by % gain from Friday's close to Monday's close: Biosite--If you bought on Friday at $55.38 and held/sold on Monday with a close of $83.80, the contestant gained 51.32% on the trade (9 out of the 10 current weekly leaders as of Monday's close bought BSTE on Friday).
French drug maker Sanofi Aventis’ board is split over whether to acquire U.S. pharmaceutical company Bristol-Myers Squibb in a deal that could be worth $54 billion, London newspaper The Times reported.
Take a company that’s being managed into the ground, add an activist investor to stir things up, and you’ve got a stock that should go higher. Tonight, Cramer’s got a play that fits the model.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.
Merck and Schering-Plough said on Monday they were beginning development of a cholesterol-lowering product that would combine their Zetia drug with Pfizer's Lipitor.
Pfizer's abandoned experimental drug torcetrapib failed to slow clogging of heart arteries even as it boosted "good" cholesterol levels, according to a study presented Monday.
Beckman Coulter, which makes products for biomedical tests, said on Sunday it would acquire Biosite for about $1.55 billion to expand its presence in the market for diagnosis and assessment of heart failure.
AstraZeneca's Crestor cholesterol drug slowed thickening in the neck arteries of people at low risk for heart attacks and strokes, but it failed to reverse thickening as researchers had hoped it would.
When Rodman and Renshaw biotech analyst Mike King told me "Genentech was gonna get its geek on," at its annual analyst meeting today I didn't realize how spot on he might be. Today the company took a deep dive into the science of its drug research and development pipeline...cabbage looper worms and all. I'm not kidding. But the ultimate geek factor came from the company's Chairman and CEO Art Levinson.
Amgen's stock fell sharply after the company said it had discontinued a key clinical trial of its drug Vectibix in combination with other drugs as an initial treatment for colon cancer. The report helped boost shares of other drugmakers such as ImClone Systems, which makes a competing drug Erbitux.
Here some of Friday's big movers on European stock markets
Stocks are edging higher ahead of the opening. Existing home sales data at 10 am New York time could influence direction but for now investors face a flurry of Friday morning corporate news headlines.
A biotech story that I've been following since I started on this beat around four or five years ago is about to go through what's referred to in the biotech world as a major "binary event". In other words, if things go well, the stock could skyrocket. If things go badly, then the stock could tank.
We've got some of the latest contest statistics on most active, widely held, etc. So, without any further introduction, here they are. The numbers are as of Tuesday, March 20, 2007.
The decision bars Teva from launching a competitor drug in the U.S. until December 2015, Pfizer said.
The grant, for Cleveland BioLabs' Protectan CBLB502, is designed to fund "development leading to the acquisition" of an radiation countermeasure.